CHISINAU, 12 Mar – RIA Novosti. Romania will continue to use the AstraZeneca vaccine against coronavirus, but will withdraw drugs from one of the batches after a problem with its use in several European countries, the National Committee for the Coordination of Vaccination Measures against Coronavirus Infection said in a statement.
Earlier, the European drug regulator – the European Medicines Agency – announced that it continues to investigate incidents with patients who received the vaccine from one batch of AstraZeneca vaccine in several EU countries and who later had thromboembolic complications, but still believes that they have not no indication that the vaccine could have caused such conditions. According to him, the ratio of thromboembolism in vaccinated AstraZeneca does not exceed this indicator among the rest of the population.
“As a precaution, it was decided to temporarily withdraw the remaining doses pending the completion of the European Medicines Agency assessment; Vaccination continues with all other vaccines of the pharmaceutical company AstraZeneca from other existing batches that are currently in Romania,” the document says.
The National Committee noted that European countries received two large doses of AstraZeneca vaccines. A shipment of ABV 5300 has been shipped to 17 countries, including Austria, Lithuania, Luxembourg and Latvia, but Romania does not have vaccines from this shipment. Italy has experienced problems with the vaccine batch ABV 2856. To date, 4,257 doses of the vaccine remain in Romania from this batch, which will be withdrawn pending verification.
Previously, the Austrian authorities decided to suspend the use of the batch of AstraZeneca vaccine as a precautionary measure due to the death of one vaccinated woman and the development of thromboembolism in another after receiving the vaccination. Following Austria, the use of the AstraZeneca party as a precautionary measure was also suspended by Estonia, Lithuania, Luxembourg and Latvia.
On Thursday, the authorities in Denmark and Norway also announced the suspension of the use of the AstraZeneca vaccine due to reports of possible blood clots after vaccinations. In Italy, the use of one batch was banned.